Clinical Trial Update: A Study to Test How Well Different Doses of BI 765250 Are Tolerated by People With a Skin Disease Called Plaque Psoriasis [Phase 1]

View source ↗

Summary

A Phase 1 trial assessing tolerability of multiple doses of BI 765250 in people with plaque psoriasis; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Psoriasis

Drugs mentioned

• BI 765250

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Psoriasis | Phase 1 | Status: COMPLETED